Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib

Academic Article
Publication Date:
2021
Short description:
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib / Casadei Gardini, A., Rovesti, G., Dadduzio, V., Vivaldi, C., Lai, E., Lonardi, S., Fornaro, L., Pretta, A., Zagonel, V., Bernardini, L., Astara, G., D'Amico, F.E., Masi, G., Rimini, M., Scartozzi, M., Cascinu, S.. - In: HPB. - ISSN 1365-182X. - 23:6(2021), pp. 915-920. [10.1016/j.hpb.2020.09.024]
abstract:
Background and aim: The aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib. Methods: 304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan–Meier method and compared with the log-rank test. Results: The concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02). Conclusion: Globally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib.
Iris type:
1.1 Articolo in rivista
List of contributors:
Casadei Gardini, A.; Rovesti, G.; Dadduzio, V.; Vivaldi, C.; Lai, E.; Lonardi, S.; Fornaro, L.; Pretta, A.; Zagonel, V.; Bernardini, L.; Astara, G.; D'Amico, F. E.; Masi, G.; Rimini, M.; Scartozzi, M.; Cascinu, S.
Authors of the University:
CASADEI GARDINI ANDREA
CASCINU STEFANO
RIMINI MARGHERITA
Handle:
https://iris.unisr.it/handle/20.500.11768/107557
Published in:
HPB
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0